Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Phase I study of pemetrexed with sorafenib in advanced solid tumors.

Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE Jr, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P.

Oncotarget. 2016 Jul 5;7(27):42625-42638. doi: 10.18632/oncotarget.9434.

2.

AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.

Agarwal S, Bell CM, Rothbart SB, Moran RG.

J Biol Chem. 2015 Nov 13;290(46):27473-86. doi: 10.1074/jbc.M115.665133. Epub 2015 Sep 21.

3.

p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.

Agarwal S, Bell CM, Taylor SM, Moran RG.

Mol Cancer Res. 2016 Jan;14(1):66-77. doi: 10.1158/1541-7786.MCR-15-0159. Epub 2015 Sep 18.

4.

Mammalian mitochondrial and cytosolic folylpolyglutamate synthetase maintain the subcellular compartmentalization of folates.

Lawrence SA, Titus SA, Ferguson J, Heineman AL, Taylor SM, Moran RG.

J Biol Chem. 2014 Oct 17;289(42):29386-96. doi: 10.1074/jbc.M114.593244. Epub 2014 Aug 27.

5.

Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation.

Nguyen T, Coover RA, Verghese J, Moran RG, Ellis KC.

ACS Med Chem Lett. 2014 Mar 7;5(5):462-7. doi: 10.1021/ml500088x. eCollection 2014 May 8.

6.

Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure.

Yang C, Xie LY, Windle JJ, Taylor SM, Moran RG.

FASEB J. 2014 May;28(5):1998-2008. doi: 10.1096/fj.13-243261. Epub 2014 Feb 14.

7.

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.

Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P.

Autophagy. 2011 Oct;7(10):1261-2. doi: 10.4161/auto.7.10.17029. Epub 2011 Oct 1.

8.

Tetrahydrofolate recognition by the mitochondrial folate transporter.

Lawrence SA, Hackett JC, Moran RG.

J Biol Chem. 2011 Sep 9;286(36):31480-9. doi: 10.1074/jbc.M111.272187. Epub 2011 Jul 15.

9.

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.

Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P.

Cancer Res. 2011 Jul 15;71(14):4955-67. doi: 10.1158/0008-5472.CAN-11-0898. Epub 2011 May 27.

10.

DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria.

Shock LS, Thakkar PV, Peterson EJ, Moran RG, Taylor SM.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3630-5. doi: 10.1073/pnas.1012311108. Epub 2011 Feb 14.

11.

Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.

Rothbart SB, Racanelli AC, Moran RG.

Cancer Res. 2010 Dec 15;70(24):10299-309. doi: 10.1158/0008-5472.CAN-10-1873.

12.

Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.

Racanelli AC, Rothbart SB, Heyer CL, Moran RG.

Cancer Res. 2009 Jul 1;69(13):5467-74. doi: 10.1158/0008-5472.CAN-08-4979. Epub 2009 Jun 23.

13.

Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase.

Tomsho JW, Moran RG, Coward JK.

Biochemistry. 2008 Aug 26;47(34):9040-50. doi: 10.1021/bi800406w. Epub 2008 Aug 2.

14.

A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression.

Racanelli AC, Turner FB, Xie LY, Taylor SM, Moran RG.

Mol Cell Biol. 2008 Jan;28(2):836-48. Epub 2007 Nov 12.

15.

Transducing particles of Staphylococcus aureus pathogenicity island SaPI1 are comprised of helper phage-encoded proteins.

Tallent SM, Langston TB, Moran RG, Christie GE.

J Bacteriol. 2007 Oct;189(20):7520-4. Epub 2007 Aug 10.

16.

Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.

Chattopadhyay S, Moran RG, Goldman ID.

Mol Cancer Ther. 2007 Feb;6(2):404-17. Review.

17.

Probing the mechanism of the hamster mitochondrial folate transporter by mutagenesis and homology modeling.

Perchiniak E, Lawrence SA, Kasten S, Woodard BA, Taylor SM, Moran RG.

Biochemistry. 2007 Feb 13;46(6):1557-67.

PMID:
17279620
18.

Modifications of human histone H3 variants during mitosis.

Garcia BA, Barber CM, Hake SB, Ptak C, Turner FB, Busby SA, Shabanowitz J, Moran RG, Allis CD, Hunt DF.

Biochemistry. 2005 Oct 4;44(39):13202-13.

PMID:
16185088
19.

Folate metabolism in plants: an Arabidopsis homolog of the mammalian mitochondrial folate transporter mediates folate import into chloroplasts.

Bedhomme M, Hoffmann M, McCarthy EA, Gambonnet B, Moran RG, Rébeillé F, Ravanel S.

J Biol Chem. 2005 Oct 14;280(41):34823-31. Epub 2005 Jul 29.

20.

A mutation inactivating the mitochondrial inner membrane folate transporter creates a glycine requirement for survival of chinese hamster cells.

McCarthy EA, Titus SA, Taylor SM, Jackson-Cook C, Moran RG.

J Biol Chem. 2004 Aug 6;279(32):33829-36. Epub 2004 May 12.

21.

A defect in the p53 response pathway induced by de novo purine synthesis inhibition.

Bronder JL, Moran RG.

J Biol Chem. 2003 Dec 5;278(49):48861-71. Epub 2003 Sep 29.

22.
23.
27.
28.

Tissue-specific expression of functional isoforms of mouse folypoly-gamma-glutamae synthetase: a basis for targeting folate antimetabolites.

Turner FB, Andreassi 2nd JL, Ferguson J, Titus S, Tse A, Taylor SM, Moran RG.

Cancer Res. 1999 Dec 15;59(24):6074-9.

29.
32.

Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate.

Tse A, Brigle K, Taylor SM, Moran RG.

J Biol Chem. 1998 Oct 2;273(40):25953-60.

34.

Transcription of the human folylpoly-gamma-glutamate synthetase gene.

Freemantle SJ, Moran RG.

J Biol Chem. 1997 Oct 3;272(40):25373-9.

35.
36.
37.

Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.

Drake JC, Allegra CJ, Moran RG, Johnston PG.

Biochem Pharmacol. 1996 May 17;51(10):1349-55.

PMID:
8787551
38.

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.

Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB.

Cancer Res. 1996 May 15;56(10):2331-5.

39.

A tribute to Dr. Gerald Burr Grindey, 1940-1993.

Mihich E, Moran RG, Nichol CA.

Invest New Drugs. 1996;14(3):241-2. No abstract available.

PMID:
8958177
40.
41.

Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.

Habeck LL, Mendelsohn LG, Shih C, Taylor EC, Colman PD, Gossett LS, Leitner TA, Schultz RM, Andis SL, Moran RG.

Mol Pharmacol. 1995 Aug;48(2):326-33.

PMID:
7651366
42.

Upstream organization of and multiple transcripts from the human folylpoly-gamma-glutamate synthetase gene.

Freemantle SJ, Taylor SM, Krystal G, Moran RG.

J Biol Chem. 1995 Apr 21;270(16):9579-84.

44.

A strategy for the design of membrane-permeable folypoly-gamma-glutamate synthetase inhibitors: "bay-region"-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs.

Sanghani PC, Jackman A, Evans VR, Thornton T, Hughes L, Calvert AH, Moran RG.

Mol Pharmacol. 1994 Feb;45(2):341-51.

PMID:
8114682
45.
46.
47.

Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.

Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, Moran RG.

J Natl Cancer Inst. 1993 Jul 21;85(14):1154-9.

PMID:
8320744
48.

Supplemental Content

Loading ...
Support Center